EdwardDAguraMD

Oncology • Dallas, TX

Hematologic Oncology

Director, Marrow Transplantation, Baylor U. Medical Center, Dallas TX

Join to view full profile

Dr. Agura is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Agura's full profile

Already have an account?

Office
3410 Worth St
Suite 300
Dallas, TX 75246
Phone+1 214-370-1513

Fax+1 214-370-1585
Is this information wrong?

Education & Training

Boston University Medical CenterResidency, Internal Medicine, 1983 - 1986
Boston University Medical CenterResidency, Internal Medicine, 1982 - 1985
Boston University Medical CenterInternship, Internal Medicine, 1982 - 1983
New York University School of MedicineClass of 1982
University of WashingtonFellowship, Medical Oncology

Certifications & Licensure

TX State Medical License 1994 - 2021

Clinical Trials

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan Regimen Start of enrollment: 2007 Mar 01
Completed
Phase 2
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma Start of enrollment: 2010 Jul 14
Completed
Phase 3
Selecting a Favorable KIR Donor in Unrelated HCT for AML Start of enrollment: 2011 Jun 01
Completed
Not Applicable
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Start of enrollment: 2011 Jun 01
Terminated
Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

19 citations
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Jason P. Cooper, Barry E. Storer, Noa Granot, Boglarka Gyurkocza, Mohamed L. Sorror, Thomas R. Chauncey, Judith A. Shizuru, Georg Franke, Michael B. Maris, Michael Boy...> ;Haematologica. 2020 Jun 4
21 citations
Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Beh...> ;British Journal of Haematology. 2020 Feb 12
10 citations
Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.
Mazyar Shadman, David G. Maloney, Barry E. Storer, Brenda M. Sandmaier, Thomas R. Chauncey, Niels Smedegaard Andersen, Dietger Niederwieser, Judith A. Shizuru, Benedet...> ;Bone Marrow Transplantation. 2020 Jan 1
6 citations
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
Haesook T. Kim, Kwang Woo Ahn, Zhen-Huan Hu, Matthew S. Davids, Virginia O. Volpe, Joseph H. Antin, Mohamed L. Sorror, Mazyar Shadman, Oliver W. Press, Joseph Pidala, ...> ;Clinical Cancer Research. 2019 Aug 15
137 citations
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee, Tamás Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, Andy I. Chen, Patrick J. Stiff, Simonetta Viviani,...> ;Blood. 2018 Dec 20
155 citations
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Beh...> ;Blood. 2018 Jul 5
26 citations
Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplanta...
Jennifer E. Vaughn, Mohamed L. Sorror, Barry E. Storer, Thomas R. Chauncey, Michael A. Pulsipher, Richard T. Maziarz, Michael B. Maris, Parameswaran Hari, Ginna G. Lap...> ;Cancer. 2015 Oct 15
31 citations
Impact of Pretransplantation 18F-fluorodeoxy Glucose–Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgki...
Veronika Bachanova, Linda J. Burns, Kwang Woo Ahn, Ginna G. Laport, Gorgun Akpek, Mohamed A. Kharfan-Dabaja, Taiga Nishihori, Edward Agura, Philippe Armand, Samantha J...> ;Biology of Blood and Marrow Transplantation. 2015 Sep 1
495 citations
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA)...
Craig H. Moskowitz, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, Andy I. Chen, Patrick J. Stiff, Alessandro M. Gianni, Angelo Mic...> ;Lancet. 2015 May 9
102 citations
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation
Christopher Bredeson, Jennifer Le-Rademacher, Kazunobu Kato, John F. DiPersio, Edward Agura, Steven M. Devine, Frederick R. Appelbaum, Marcie Tomblyn, Ginna G. Laport,...> ;Blood. 2013 Dec 5
159 citations
Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation
Rainer Storb, Boglarka Gyurkocza, Barry E. Storer, Mohamed L. Sorror, Karl G. Blume, Dietger Niederwieser, Thomas R. Chauncey, Michael A. Pulsipher, Finn Bo Petersen, ...> ;Journal of Clinical Oncology. 2013 Apr 20
230 citations
Long-Term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies
Mohamed L. Sorror, Brenda M. Sandmaier, Barry E. Storer, Georg Franke, Ginna G. Laport, Thomas R. Chauncey, Edward Agura, Richard T. Maziarz, Amelia Langston, Paramesw...> ;JAMA. 2011 Nov 2
26 citations
Report of a Phase II Study of Clofarabine and Cytarabine in De Novo and Relapsed and Refractory AML Patients and in Selected Elderly Patients at High Risk for Anthracy...
Edward Agura, Barry Cooper, Houston Holmes, Estil Vance, Robert Brian Berryman, Christopher Maisel, Sandy Li, Giovanna Saracino, Mirjana Tadic-Ovcina, Joseph Fay> ;The Oncologist. 2011 Feb 1
176 citations
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia
Boglarka Gyurkocza, Rainer Storb, Barry E. Storer, Thomas R. Chauncey, Thoralf Lange, Judith A. Shizuru, Amelia Langston, Michael A. Pulsipher, Christopher Bredeson, R...> ;Journal of Clinical Oncology. 2010 Jun 10
79 citations
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
Marcello Rotta, Barry E. Storer, Firoozeh Sahebi, Judith A. Shizuru, Benedetto Bruno, Thoralf Lange, Edward Agura, Peter A. McSweeney, Michael A. Pulsipher, Parameswar...> ;Blood. 2009 Apr 2
83 citations
Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.
Andrew R. Rezvani, Lalitha Norasetthada, Ted Gooley, Mohamed L. Sorror, Michelle E. Bouvier, Firoozeh Sahebi, Edward Agura, Thomas R. Chauncey, Richard T. Maziarz, Mic...> ;British Journal of Haematology. 2008 Nov 1
214 citations
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Mohamed L. Sorror, Barry E. Storer, Brenda M. Sandmaier, Michael B. Maris, Judith A. Shizuru, Richard T. Maziarz, Edward Agura, Thomas R. Chauncey, Michael A. Pulsiphe...> ;Journal of Clinical Oncology. 2008 Oct 20
70 citations
The National Marrow Donor Program 20 Years of Unrelated Donor Hematopoietic Cell Transplantation
Karen K. Ballen, Roberta King, Pintip Chitphakdithai, Charles D. Bolan, Edward Agura, Robert J. Hartzman, Nancy A. Kernan> ;Biology of Blood and Marrow Transplantation. 2008 Sep 1
74 citations
Twenty Years of Unrelated Donor Hematopoietic Cell Transplantation for Adult Recipients Facilitated by the National Marrow Donor Program
Chatchada Karanes, Gene Nelson, Pintip Chitphakdithai, Edward Agura, Karen K. Ballen, Charles D. Bolan, David L. Porter, Joseph P. Uberti, Roberta King, Dennis L. Confer> ;Biology of Blood and Marrow Transplantation. 2008 Sep 1
108 citations
Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders
Ginna G. Laport, Brenda M. Sandmaier, Barry E. Storer, Bart L. Scott, Monic J. Stuart, Thoralf Lange, Michael B. Maris, Edward Agura, Thomas R. Chauncey, Ruby M. Wong,...> ;Biology of Blood and Marrow Transplantation. 2008 Feb 1
158 citations
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma
Andrew R. Rezvani, Barry E. Storer, Michael B. Maris, Mohamed L. Sorror, Edward Agura, Richard T. Maziarz, James C. Wade, Thomas R. Chauncey, Stephen J. Forman, Thoral...> ;Journal of Clinical Oncology. 2008 Jan 10
63 citations
Progress in the treatment of acute myeloid leukemia.
Farhad Ravandi, Alan Kenneth Burnett, Edward Agura, Hagop M. Kantarjian> ;Cancer. 2007 Nov 1
139 citations
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
Christoph Kahl, Barry E. Storer, Brenda M. Sandmaier, Marco Mielcarek, Michael B. Maris, Karl G. Blume, Dietger Niederwieser, Thomas R. Chauncey, Stephen J. Forman, Ed...> ;Blood. 2007 Oct 1
34 citations
Acute graft-versus-host disease after liver transplantation: role of withdrawal of immunosuppression in therapeutic management.
Srinath Chinnakotla, Douglas M. Smith, Rana Domiati-Saad, Edward Agura, David L. Watkins, George J. Netto, Tadahiro Uemura, Edmund Q. Sanchez, Marlon F. Levy, Goran B....> ;Liver Transplantation. 2007 Jan 1
75 citations
Factors Associated With Outcomes in Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning After Failed Myeloablative Hematopoietic Cell Tran...
Frédéric Baron, Rainer Storb, Barry E. Storer, Michael B. Maris, Dietger Niederwieser, Judith A. Shizuru, Thomas R. Chauncey, Benedetto Bruno, Stephen J. Forman, Peter...> ;Journal of Clinical Oncology. 2006 Sep 1
Join now to see all

Journal Articles

Five-Year PFS from the AETHERA Trial of Brentuximab Vedotin for Hodgkin Lymphoma at High Risk of Progression or Relapse
Patrick Stiff, Edward Agura, Craig H Moskowitz, John Sweetenham, Auayporn Nademanee, Veronika Bachanova, Blood